Probability of survival without aHUS relapse after eculizumab discontinuation according to level of sC5b-9 at inclusion in the entire cohort. Risk of relapse was higher in patients with elevated sC5b-9 at inclusion compared with those with normal sC5b-9 levels (P = .02 by log-rank test).